1. Apoptosis
  2. RIP kinase
  3. GSK-872 hydrochloride

GSK-872 hydrochloride 

目录号: HY-101872A 纯度: 99.64%
产品使用指南

GSK-872 hydrochloride 是 RIPK3 抑制剂,高亲和力结合 RIP3 激酶结构域,IC50为1.8 nM,并抑制激酶活性,IC50为1.3 nM。GSK-872 hydrochloride 降低 RIPK3 介导的坏死 (necroptosis) 和随后的 HMGB1 的细胞质易位和表达,并改善早期脑损伤中的脑水肿和神经功能缺损。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

GSK-872 hydrochloride Chemical Structure

GSK-872 hydrochloride Chemical Structure

CAS No. : 2703752-81-0

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥990
In-stock
5 mg ¥900
In-stock
10 mg ¥1500
In-stock
25 mg ¥3300
In-stock
50 mg ¥5900
In-stock
100 mg ¥9200
In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of GSK-872 hydrochloride:

注册 MCE会员完成审核
即刻享有 积分商城 300 专属积分

Top Publications Citing Use of Products

    GSK-872 hydrochloride purchased from MCE. Usage Cited in: J Immunol. 2018 Apr 15;200(8):2826-2834.

    Wild-type BMDMs are treated with or without PM (20 μg/ml), and DMSO, Necrostatin-1 (10 μM), and GSK’872 (5 μM) as indicated, the expression of p-IkBα and p-RELA are measured by Western blot.

    GSK-872 hydrochloride purchased from MCE. Usage Cited in: Chin J of Oncol Prev and Treat. 2018, 10(2): 105-109.

    In the inhibitor group,GSK'872 is injected intrathecally at 30 min before model establishment; in the saline group,the same volume of saline is intrathecally injected.

    GSK-872 hydrochloride purchased from MCE. Usage Cited in: Transl Stroke Res. 2021 Dec;12(6):991-1017.

    Delayed administration of GSK-872 reduces the protein level of RIP3K or MLKL and GFAP after OGD/Re injury. Astrocytes are exposed to OGD for 6 h followed by reoxygenation for 24 h. GSK-872 (10 μM) is added to the cells upon reoxygenation.
    • 生物活性

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    GSK-872 hydrochloride is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 hydrochloride decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury[1][2][3].

    IC50 & Target

    IC50: 1.3 nM (RIPK3)[1]

    体外研究
    (In Vitro)

    GSK-872 (GSK'872; 0.01-3 μM; 24 hours) blocks TNF-induced necroptosis in human HT-29 cells in a concentration-dependent manner[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[1]

    Cell Line: HT-29 cells
    Concentration: 0.01, 0.03 , 0.1, 0.3, 1, and 3 μM
    Incubation Time: 24 hours
    Result: Blocked TNF-induced necroptosis in a concentration-dependent manner.
    体内研究
    (In Vivo)

    GSK-872 hydrochloride (25 mM; intracerebroventricular injection) can attenuate brain edema and improve neurological function following subarachnoid hemorrhage (SAH) and reduce the number of necrotic cells. GSK-872 hydrochloride can also decrease the protein levels of RIPK3 and MLKL, and cytoplasmic translocation and expression of HMGB1, an important pro-inflammatory protein[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Eight weeks old Sprague-Dawley male rats with 300-320 g body weight (rat SAH model)[3]
    Dosage: 25 mM/6 μL
    Administration: Syringe pump (intracerebroventricular) at 30 min after SAH
    Result: Attenuated brain edema, improved neurological function and decreased the number of necrotic cells in the ipsilateral cortex. Decreased the expression of RIPK3, MLKL and cytoplasmic HMGB1 at 72 h after SAH in the ipsilateral cortex.
    分子量

    419.95

    Formula

    C19H18ClN3O2S2

    CAS 号
    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    溶解性数据
    In Vitro: 

    DMSO : 10 mg/mL (23.81 mM; ultrasonic and warming and heat to 60°C)

    H2O : 2.5 mg/mL (5.95 mM; ultrasonic and warming and heat to 60°C)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 2.3812 mL 11.9062 mL 23.8124 mL
    5 mM 0.4762 mL 2.3812 mL 4.7625 mL
    10 mM 0.2381 mL 1.1906 mL 2.3812 mL
    *

    请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

    In Vivo:

    请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
    分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

    • 1.

      请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 0.21 mg/mL (0.50 mM); Clear solution

      此方案可获得 ≥ 0.21 mg/mL (0.50 mM,饱和度未知) 的澄清溶液。

      以 1 mL 工作液为例,取 100 μL 2.1 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

      将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液
    *以上所有助溶剂都可在 MCE 网站选购。
    参考文献
    • 摩尔计算器

    • 稀释计算器

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量   浓度   体积   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
    × = ×
    C1   V1   C2   V2

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    GSK-872 hydrochloride
    目录号:
    HY-101872A
    需求量: